Please Wait.....
Report
Global Pediatric Vaccines Market By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines), By Indication (Varicella, Diphtheria, Pertussis and Tetanus, Influenza, Human Papilloma Virus, Measles, Mumps and Rubella, Meningococcal Disease, Pneumococcal Disease, Polio, Rotavirus, Other Indications): Global Opportunity Analysis and Industry Forecast, 2021-2031
Market Report I 2022-11-01 I 310 Pages I Allied Market Research
Theglobal pediatric vaccine market accounted for $2,1371.73 million in 2021, and is expected to reach $ 3,6390.99 million by 2031, registering a CAGR of 5.4% from 2022 to 2031.
Pediatric vaccine is a biological preparation that is administered to produce acquired immunity in children. Administration of vaccines aids to enhance immune response against a specific pathogen. Pediatric vaccinations play a key role in sustaining children health across different countries; hence, they are used in various national disease-prevention strategies. Owing to the increased occurrence of both viral and bacterial infectious diseases, the demand for vaccines has grown over the past few years. Pediatric vaccinations are primarily provided to children of different ages, improving their immune system during their lives and ensuring defense against various forms of infectious diseases.
It is estimated that pediatric vaccine market is expected to experience significant market growth during the forecast period as there has been surge in adoption in several countries across the globe in the national immunization programs. In addition, rise in prevalence of pneumococcal, influenza, and meningococcal disease in several countries has led to upsurge in demand for vaccines, which further facilitate the growth of the market. However, stringent government regulations for the approval of new vaccines and recall of several products are expected to impede the market growth. In contrast, rise in demand in emerging markets, increase in R&D activities to develop new vaccines, and surge in healthcare spending are anticipated to provide significant growth opportunities for the pediatric vaccine market.
The pediatric vaccine market is segmented on the basis of type, technology, indication, and region. On the basis of type, the market is bifurcated into monovalent and multivalent. Depending on technology, it is classified into live attenuated vaccines, inactivated vaccines, toxoid vaccines, and subunit, recombinant, polysaccharide, and conjugate vaccines. By indication, it is classified into varicella, diphtheria, pertussis & tetanus, influenza, human papilloma virus, measles, mumps & rubella, meningococcal disease, pneumococcal disease, polio, rotavirus, and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides a comprehensive analysis of the key players that operate in the global pediatric vaccine market. Key companies profiled in the report include Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, AstraZeneca plc. GlaxoSmithKline plc., Sanofi Aventis, Merck & Co., Inc., Emergent BioSolutions Inc., CSL Limited, and Novavax, Inc.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global paediatric vaccine market analysis from 2021 to 2031 to identify the prevailing global paediatric vaccine market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the global paediatric vaccine market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global global paediatric vaccine market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Technology
- Live Attenuated Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
By Type
- Monovalent
- Multivalent
By Indication
- Varicella
- Measles, Mumps and Rubella
- Meningococcal Disease
- Pneumococcal Disease
- Polio
- Rotavirus
- Diphtheria, Pertussis and Tetanus
- Influenza
- Human Papilloma Virus
- Other Indications
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest Of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
- Key Market Players
- AstraZeneca Plc.
- CSL Limited
- Emergent BioSolutions Inc.
- GlaxoSmithKline plc.
- Johnson & Johnson
- Merck & Co., Inc.
- Novavax, Inc.
- Pfizer Inc.
- Sanofi Aventis
- Serum Institute of India Pvt. Ltd.
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Monovalent
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Multivalent
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
CHAPTER 5: GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY
5.1 Overview
5.1.1 Market size and forecast
5.2 Live Attenuated Vaccines
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Inactivated Vaccines
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
5.4 Toxoid Vaccines
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market share analysis by country
5.5 Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market share analysis by country
CHAPTER 6: GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Varicella
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Diphtheria, Pertussis and Tetanus
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Influenza
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
6.5 Human Papilloma Virus
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market share analysis by country
6.6 Measles, Mumps and Rubella
6.6.1 Key market trends, growth factors and opportunities
6.6.2 Market size and forecast, by region
6.6.3 Market share analysis by country
6.7 Meningococcal Disease
6.7.1 Key market trends, growth factors and opportunities
6.7.2 Market size and forecast, by region
6.7.3 Market share analysis by country
6.8 Pneumococcal Disease
6.8.1 Key market trends, growth factors and opportunities
6.8.2 Market size and forecast, by region
6.8.3 Market share analysis by country
6.9 Polio
6.9.1 Key market trends, growth factors and opportunities
6.9.2 Market size and forecast, by region
6.9.3 Market share analysis by country
7.0 Rotavirus
7.0.1 Key market trends, growth factors and opportunities
7.0.2 Market size and forecast, by region
7.0.3 Market share analysis by country
7.1 Other Indications
7.1.1 Key market trends, growth factors and opportunities
7.1.2 Market size and forecast, by region
7.1.3 Market share analysis by country
CHAPTER 7: GLOBAL PEDIATRIC VACCINES MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Technology
7.2.4 North America Market size and forecast, by Indication
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Type
7.2.5.1.3 Market size and forecast, by Technology
7.2.5.1.4 Market size and forecast, by Indication
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Type
7.2.5.2.3 Market size and forecast, by Technology
7.2.5.2.4 Market size and forecast, by Indication
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Type
7.2.5.3.3 Market size and forecast, by Technology
7.2.5.3.4 Market size and forecast, by Indication
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Technology
7.3.4 Europe Market size and forecast, by Indication
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Type
7.3.5.1.3 Market size and forecast, by Technology
7.3.5.1.4 Market size and forecast, by Indication
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Type
7.3.5.2.3 Market size and forecast, by Technology
7.3.5.2.4 Market size and forecast, by Indication
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Type
7.3.5.3.3 Market size and forecast, by Technology
7.3.5.3.4 Market size and forecast, by Indication
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Type
7.3.5.4.3 Market size and forecast, by Technology
7.3.5.4.4 Market size and forecast, by Indication
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Type
7.3.5.5.3 Market size and forecast, by Technology
7.3.5.5.4 Market size and forecast, by Indication
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Type
7.3.5.6.3 Market size and forecast, by Technology
7.3.5.6.4 Market size and forecast, by Indication
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Technology
7.4.4 Asia-Pacific Market size and forecast, by Indication
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 China
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Type
7.4.5.1.3 Market size and forecast, by Technology
7.4.5.1.4 Market size and forecast, by Indication
7.4.5.2 Japan
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Type
7.4.5.2.3 Market size and forecast, by Technology
7.4.5.2.4 Market size and forecast, by Indication
7.4.5.3 India
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Type
7.4.5.3.3 Market size and forecast, by Technology
7.4.5.3.4 Market size and forecast, by Indication
7.4.5.4 Australia
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Type
7.4.5.4.3 Market size and forecast, by Technology
7.4.5.4.4 Market size and forecast, by Indication
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Type
7.4.5.5.3 Market size and forecast, by Technology
7.4.5.5.4 Market size and forecast, by Indication
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Type
7.4.5.6.3 Market size and forecast, by Technology
7.4.5.6.4 Market size and forecast, by Indication
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Technology
7.5.4 LAMEA Market size and forecast, by Indication
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Type
7.5.5.1.3 Market size and forecast, by Technology
7.5.5.1.4 Market size and forecast, by Indication
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Type
7.5.5.2.3 Market size and forecast, by Technology
7.5.5.2.4 Market size and forecast, by Indication
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Type
7.5.5.3.3 Market size and forecast, by Technology
7.5.5.3.4 Market size and forecast, by Indication
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Type
7.5.5.4.3 Market size and forecast, by Technology
7.5.5.4.4 Market size and forecast, by Indication
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 AstraZeneca Plc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 CSL Limited
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Emergent BioSolutions Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 GlaxoSmithKline plc.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Johnson & Johnson
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Merck & Co., Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Novavax, Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Pfizer Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Sanofi Aventis
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Serum Institute of India Pvt. Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 2. GLOBAL PEDIATRIC VACCINES MARKET FOR MONOVALENT, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. GLOBAL PEDIATRIC VACCINES MARKET FOR MONOVALENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. GLOBAL PEDIATRIC VACCINES MARKET FOR MULTIVALENT, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. GLOBAL PEDIATRIC VACCINES MARKET FOR MULTIVALENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 6. GLOBAL GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 7. GLOBAL PEDIATRIC VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 8. GLOBAL PEDIATRIC VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 9. GLOBAL PEDIATRIC VACCINES MARKET FOR INACTIVATED VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. GLOBAL PEDIATRIC VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 11. GLOBAL PEDIATRIC VACCINES MARKET FOR TOXOID VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. GLOBAL PEDIATRIC VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 13. GLOBAL PEDIATRIC VACCINES MARKET FOR SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. GLOBAL PEDIATRIC VACCINES MARKET FOR SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 15. GLOBAL GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. GLOBAL PEDIATRIC VACCINES MARKET FOR VARICELLA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 17. GLOBAL PEDIATRIC VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 18. GLOBAL PEDIATRIC VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS AND TETANUS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 19. GLOBAL PEDIATRIC VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS AND TETANUS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 20. GLOBAL PEDIATRIC VACCINES MARKET FOR INFLUENZA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 21. GLOBAL PEDIATRIC VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 22. GLOBAL PEDIATRIC VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 23. GLOBAL PEDIATRIC VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 24. GLOBAL PEDIATRIC VACCINES MARKET FOR MEASLES, MUMPS AND RUBELLA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 25. GLOBAL PEDIATRIC VACCINES MARKET FOR MEASLES, MUMPS AND RUBELLA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 26. GLOBAL PEDIATRIC VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 27. GLOBAL PEDIATRIC VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 28. GLOBAL PEDIATRIC VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 29. GLOBAL PEDIATRIC VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 30. GLOBAL PEDIATRIC VACCINES MARKET FOR POLIO, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 31. GLOBAL PEDIATRIC VACCINES MARKET FOR POLIO, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 32. GLOBAL PEDIATRIC VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 33. GLOBAL PEDIATRIC VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 34. GLOBAL PEDIATRIC VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 35. GLOBAL PEDIATRIC VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 36. GLOBAL PEDIATRIC VACCINES MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 37. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 38. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 39. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 40. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 41. U.S. GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 42. U.S. GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 43. U.S. GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 44. CANADA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 45. CANADA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 46. CANADA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 47. MEXICO GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 48. MEXICO GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 49. MEXICO GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 50. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 51. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 52. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 53. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 54. GERMANY GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 55. GERMANY GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 56. GERMANY GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 57. FRANCE GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 58. FRANCE GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 59. FRANCE GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 60. UK GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 61. UK GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 62. UK GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 63. ITALY GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 64. ITALY GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 65. ITALY GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 66. SPAIN GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 67. SPAIN GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 68. SPAIN GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 69. REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 70. REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 71. REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 72. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 73. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 74. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 75. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 76. CHINA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 77. CHINA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 78. CHINA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 79. JAPAN GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 80. JAPAN GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 81. JAPAN GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 82. INDIA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 83. INDIA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 84. INDIA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 85. AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 86. AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 87. AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 88. SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 89. SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 90. SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 91. REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 92. REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 93. REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 94. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 95. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 96. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 97. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 98. BRAZIL GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 99. BRAZIL GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 100. BRAZIL GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 101. SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 102. SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 103. SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 104. SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 105. SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 106. SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 107. REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 108. REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 109. REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 110.ASTRAZENECA PLC.: COMPANY SNAPSHOT
TABLE 111.ASTRAZENECA PLC.: OPERATING SEGMENTS
TABLE 112.ASTRAZENECA PLC.: PRODUCT PORTFOLIO
TABLE 113.ASTRAZENECA PLC.: NET SALES
TABLE 114.ASTRAZENECA PLC.: KEY STRATERGIES
TABLE 115.CSL LIMITED: COMPANY SNAPSHOT
TABLE 116.CSL LIMITED: OPERATING SEGMENTS
TABLE 117.CSL LIMITED: PRODUCT PORTFOLIO
TABLE 118.CSL LIMITED: NET SALES
TABLE 119.CSL LIMITED: KEY STRATERGIES
TABLE 120.EMERGENT BIOSOLUTIONS INC.: COMPANY SNAPSHOT
TABLE 121.EMERGENT BIOSOLUTIONS INC.: OPERATING SEGMENTS
TABLE 122.EMERGENT BIOSOLUTIONS INC.: PRODUCT PORTFOLIO
TABLE 123.EMERGENT BIOSOLUTIONS INC.: NET SALES
TABLE 124.EMERGENT BIOSOLUTIONS INC.: KEY STRATERGIES
TABLE 125.GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 126.GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
TABLE 127.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 128.GLAXOSMITHKLINE PLC.: NET SALES
TABLE 129.GLAXOSMITHKLINE PLC.: KEY STRATERGIES
TABLE 130.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 131.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 132.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 133.JOHNSON & JOHNSON: NET SALES
TABLE 134.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 135.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 136.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 137.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 138.MERCK & CO., INC.: NET SALES
TABLE 139.MERCK & CO., INC.: KEY STRATERGIES
TABLE 140.NOVAVAX, INC.: COMPANY SNAPSHOT
TABLE 141.NOVAVAX, INC.: OPERATING SEGMENTS
TABLE 142.NOVAVAX, INC.: PRODUCT PORTFOLIO
TABLE 143.NOVAVAX, INC.: NET SALES
TABLE 144.NOVAVAX, INC.: KEY STRATERGIES
TABLE 145.PFIZER INC.: COMPANY SNAPSHOT
TABLE 146.PFIZER INC.: OPERATING SEGMENTS
TABLE 147.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 148.PFIZER INC.: NET SALES
TABLE 149.PFIZER INC.: KEY STRATERGIES
TABLE 150.SANOFI AVENTIS: COMPANY SNAPSHOT
TABLE 151.SANOFI AVENTIS: OPERATING SEGMENTS
TABLE 152.SANOFI AVENTIS: PRODUCT PORTFOLIO
TABLE 153.SANOFI AVENTIS: NET SALES
TABLE 154.SANOFI AVENTIS: KEY STRATERGIES
TABLE 155.SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
TABLE 156.SERUM INSTITUTE OF INDIA PVT. LTD.: OPERATING SEGMENTS
TABLE 157.SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
TABLE 158.SERUM INSTITUTE OF INDIA PVT. LTD.: NET SALES
TABLE 159.SERUM INSTITUTE OF INDIA PVT. LTD.: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1.GLOBAL PEDIATRIC VACCINES MARKET SEGMENTATION
FIGURE 2.GLOBAL PEDIATRIC VACCINES MARKET,2021-2031
FIGURE 3.GLOBAL PEDIATRIC VACCINES MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.GLOBAL PEDIATRIC VACCINES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.GLOBAL PEDIATRIC VACCINES MARKET,BY TYPE,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF MONOVALENT GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF MULTIVALENT GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 15.GLOBAL PEDIATRIC VACCINES MARKET,BY TECHNOLOGY,2021(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF LIVE ATTENUATED VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF INACTIVATED VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF TOXOID VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 20.GLOBAL PEDIATRIC VACCINES MARKET,BY INDICATION,2021(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF VARICELLA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF DIPHTHERIA, PERTUSSIS AND TETANUS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF INFLUENZA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HUMAN PAPILLOMA VIRUS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF MEASLES, MUMPS AND RUBELLA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF MENINGOCOCCAL DISEASE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF PNEUMOCOCCAL DISEASE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 28.COMPARATIVE SHARE ANALYSIS OF POLIO GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 29.COMPARATIVE SHARE ANALYSIS OF ROTAVIRUS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 30.COMPARATIVE SHARE ANALYSIS OF OTHER INDICATIONS GLOBAL PEDIATRIC VACCINES MARKET,2021-2031(%)
FIGURE 31.GLOBAL PEDIATRIC VACCINES MARKET BY REGION,2021
FIGURE 32.U.S. GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 33.CANADA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 34.MEXICO GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 35.GERMANY GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 36.FRANCE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 37.UK GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 38.ITALY GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 39.SPAIN GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 40.REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 41.CHINA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 42.JAPAN GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 43.INDIA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 44.AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 45.SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 46.REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 47.BRAZIL GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 48.SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 49.SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 50.REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET,2021-2031($MILLION)
FIGURE 51. TOP WINNING STRATEGIES, BY YEAR
FIGURE 52. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 53. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 54.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 55.COMPETITIVE DASHBOARD
FIGURE 56.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 57.ASTRAZENECA PLC..: NET SALES ($MILLION)
FIGURE 58.CSL LIMITED.: NET SALES ($MILLION)
FIGURE 59.EMERGENT BIOSOLUTIONS INC..: NET SALES ($MILLION)
FIGURE 60.GLAXOSMITHKLINE PLC..: NET SALES ($MILLION)
FIGURE 61.JOHNSON & JOHNSON.: NET SALES ($MILLION)
FIGURE 62.MERCK & CO., INC..: NET SALES ($MILLION)
FIGURE 63.NOVAVAX, INC..: NET SALES ($MILLION)
FIGURE 64.PFIZER INC..: NET SALES ($MILLION)
FIGURE 65.SANOFI AVENTIS.: NET SALES ($MILLION)
FIGURE 66.SERUM INSTITUTE OF INDIA PVT. LTD..: NET SALES ($MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security